FOLFOX肝动脉灌注化疗联合仑伐替尼和PD-1抑制剂治疗中晚期原发性肝癌患者疗效研究*

doi:10.3969/j.issn.1672-5069.2025.03.027

Abstract

Abstract: Objective The aim of this study was to investigate therapeutic efficacy of FOLFOX in hepatic artery infusion chemotherapy (HAIC) with combination of lenvatinib and PD-1 inhibitors in treatment of patients with advanced primary liver cancer(PLC). Methods 86 patients with advanced, unresectable PLC were encountered in our hospital between January 2020 and December 2022, and were randomly assigned to receive FOLFOX through HAIC chemotherapy plus lenvatinib in 43 patients (control), or to receive sintilimab at base of regimen mentioned above in another 43 patients (observation) for three months, and followed-up for two years. Peripheral blood lymphocyte subsets were detected by FCM, and serum alpha-fetoprotein (AFP) level was assayed by ELISA. Results Complete remission rate and partial remission rate in the observation group were 11.6% and 74.4%, with total effective rate of 86.1%, both significantly higher than 4.7% and 60.5%, with total effective rate of 65.1%(P＜0.05) in the control; after treatment, percentages of peripheral blood CD3⁺ and CD4⁺ cells were (46.9±5.3)% and (40.4±5.2)%, both much higher than [(40.4±4.8)% and (34.1±4.3)%, respectively, P＜0.05], while percentage of CD8⁺ cells was (16.1±2.4)%, much lower than [(22.3±3.5)%, P＜0.05) in the control; serum AFP level was (102.6±11.2)ng/mL, much lower than [(143.0±15.4)ng/mL, P＜0.05]in the control group; serum ALT and AST levels were (49.0±4.0)U/L and (44.4±5.0)U/L, both much higher than [(41.8±4.8)U/L and (38.2±5.3)U/L, respectively, P＜0.05]in the control; by end of two-year follow-up, the survival rate in the observation group was 67.4%, with progression-free survival (PFS) of (16.2±2.8)m, significantly higher than 39.5%, with PFS of (11.8±3.2)m in the control (P＜0.05). Conclusion The combination of FOLFOX through HAIC and Lenvatinib plus sintilimab in dealing with patients with advanced PLC could elevate short-term remission rate and prolong survival, and warrants further clinical investigation.

Key words: Hepatoma, FOLFOX regimen, Hepatic artery infusion chemotherapy, Lenvatinib, Sintilimab monoclonal antibody, Therapy

Yang Yijin, Hong Han, Chen Bin, et al. FOLFOX in hepatic artery infusion chemotherapy with combination of lenvatinib and PD-1 inhibitors in treatment of patients with advanced primary liver cancer[J]. Journal of Practical Hepatology, 2025, 28(3): 426-429.

References

[1] Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends, 2021,15(3):155-160.
[2] France NL, Blair HA. Tremelimumab: a review in advanced or unresectable hepatocellular carcinoma. Target Oncol, 2024, 19(1):115-123.
[3] Zhang B, Huang B, Yang F, et al. High-risk hepatocellular carcinoma: hepaticarterial infusion chemotherapy versus transarterial chemoembolization. J Hepatocell Carcinoma, 2024,11:651-663.
[4] Zhang Y, Qin S, Chao J,et al. The in-vitro antitumor effects of AST-3424 monotherapy and combination therapy with oxaliplatin or 5-fluorouracil in primary liver cancer. Front Oncol, 2022,12:885139.
[5] Ventura C, Junco M, Santiago Valtierra FX,et al. Synergism of small molecules targeting VDAC with sorafenib, regorafenib or lenvatinib on hepatocarcinoma cell proliferation and survival. Eur J Pharmacol, 2023, 957:176034.
[6] Villacampa G, Cresta Morgado P, Navarro V,et al. Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy. Cancer Treat Rev, 2023, 116:102542.
[7] Diao L, Wang C, You R,et al. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE. J Gastroenterol Hepatol, 2024, 39(4):746-753.
[8] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019 年版). 中华肝脏病杂志, 2020, 28(2):112-128.
[9] Jiang X, Aljbri A, Liu J,et al. Hepatic arterial infusion chemotherapy with implantable arterial access port for advanced-stage hepatocellular carcinoma: a case report. Front Oncol, 2024, 14:1401882.
[10] Liang RB, Zhao Y, He MK,et al. Hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin with or without sorafenib as initial treatment for advanced hepatocellular carcinoma. Front Oncol, 2021, 11:619461.
[11] Mei J, Yu H,Qin L,et al. FOLFOX-HAIC for unresectable large hepatocellular carcinoma: the effectiveness has yet to be determined. J Clin Oncol, 2022, 40(16):1841.
[12] Liu BJ, Gao S, Zhu X,et al. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy, 2021, 13(17):1395-1405.
[13] Nathan J, Shameera R, Palanivel G. Studying molecular signaling in major angiogenic diseases. Mol Cell Biochem, 2022, 477(10):2433-2450.
[14] Filippone A, Lanza M, Mannino D, et al. PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression. Cancer Immunol Immunother, 2022, 71(9):2067-2075.
[15] Glorieux C, Cui L, Zeng P,et al. Diverse effects ofchemotherapeutic agents on immune cell function and implications in immunochemotherapy. Cancer Commun (Lond), 2021, 41(5):432-435.
[16] Iesato A, Li S, Sadow PM,et al. The tyrosine kinase inhibitor lenvatinib inhibits anaplastic thyroid carcinoma growth bytargeting pericytes in the tumor microenvironment. Thyroid, 2023, 33(7):835-848.
[17] Zhong SJ, Liu X, Kaneko T,et al. Peptide blockers of PD-1-PD-L1 interaction reinvigorate PD-1-Suppressed T cells and curb tumor growth in mice. Cells, 2024, 13(14):1193.
[18] Li M, Liao J, Wang L,et al. A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy. Front Immunol, 2024, 15:1303259.
[19] 刘禹辰,朱建交,陶计林,等. 肝动脉灌注化疗联合仑伐替尼、卡瑞利珠单抗治疗不可切除肝癌的临床观察. 中国药物应用与监测,2023,20(4):221-225.
[20] Yin J, Wu Y, Yang X,et al. Checkpoint inhibitor pneumonitis induced by anti-PD-1/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism. Front Immunol, 2022, 13:830631.

FOLFOX in hepatic artery infusion chemotherapy with combination of lenvatinib and PD-1 inhibitors in treatment of patients with advanced primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Luo Yuexin, Luo Hongchun. Interleukin-2 in the treatment of patients with autoimmune hepatitis: current state of the art, controversies, and perspectives [J]. Journal of Practical Hepatology, 2025, 28(3): 330-333.
[2]	Kong Lixia, Chen Xufeng, Xu Yan, et al. Sequential or combined rescue antiviral therapy by tenofovir amibufenamide in entecavir-treated chronic hepatitis B patients with low-level viremia [J]. Journal of Practical Hepatology, 2025, 28(3): 334-337.
[3]	Wang Hao, Wang Qingyuan, Shen Qiong, et al. Satisfactory response to pegylated interferon α-2a and albavir/granrivir combination therapy in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2025, 28(3): 346-349.
[4]	Xu Lingling, Lu Yuan, Zheng Yanchai, et al. Improvement of liver function tests by oral bicyclol in patients with type 2 diabetes mellitus and nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(3): 358-361.
[5]	Wen Dachao, Zhang Qiuping, Shi Ling. Short-term observation of acupoint application and exercise in the treatment of patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 370-373.
[6]	Ma Dantong, Yang Shuang, Gao Lili, et al. Clinical feature of patients with drug-induced autoimmune-like hepatitis: An analysis of 73 cases [J]. Journal of Practical Hepatology, 2025, 28(3): 390-393.
[7]	Li Yongfei, Xu Zhengju, Ye Qiaoxia, et al. Efficacy of plasma exchange and hemofiltration in the treatment of patients with acute-on-chronic hepatitis B liver failure [J]. Journal of Practical Hepatology, 2025, 28(3): 394-397.
[8]	Xu Rongbo, Wang Yan, Wang Xiaosong, et al. Efficacy of endoscopic variceal ligation and somatostatin and esomeprazole combination in the treatment of patients with liver cirrhosis with complicated esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2025, 28(3): 410-413.
[9]	Jiang Zhaoqin, Song Jie, Mu Yongfang. Efficacy of endoscopic variceal ligation with combination of intravenous administration of somatostatin and omeprazole in the treatment of liver cirrhosis patients with esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2025, 28(3): 422-425.
[10]	Dong Yanhong, Jiang Kun, Huang Hui, et al. MRI evaluation of intrahepatic residual lesions in patients with primary liver cancer after transcatheter arterial chemoembolization [J]. Journal of Practical Hepatology, 2025, 28(3): 434-437.
[11]	Sha Xinjie, Xia Xiaoliang. Diagnosis of benign and malignant liver tumors by magnetic resonance imaging enhancement scanning and diffusion-weighted imaging [J]. Journal of Practical Hepatology, 2025, 28(3): 438-441.
[12]	Li Hongjian, Xu Zhiwen, Xia Fei, et al. Intrapurulent catheter drainage under ultrasound guidance in the treatment of patients with bacterial liver abscess [J]. Journal of Practical Hepatology, 2025, 28(3): 454-457.
[13]	Yan Huajun, Chen Xingyun, Ma Bing, et al. Ultrasound-guided percutaneous transhepatic gallbladder puncture drainage and subsequent selective laparoscopic cholecystectomy in treatment of patients with acute calculous obstructive cholecystitis [J]. Journal of Practical Hepatology, 2025, 28(3): 458-461.
[14]	Feng Song, Li lianjie, Cheng Bo. Percutaneous transhepatic gallbladder drainage and sequential laparoscopic cholecystectomy with preservation of main cystic artery in the treatment of patients with acute cholecystitis [J]. Journal of Practical Hepatology, 2025, 28(3): 462-465.
[15]	Ke Junjie, Xing Jieyu, Zhang Mingying. Comparison of endoscopic retrograde cholangiopancreatography and laparoscopic choledochotomy and exploration in the treatment of patients with post-cholecystectomy choledocholithiasis [J]. Journal of Practical Hepatology, 2025, 28(3): 466-469.